We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
15
May 2026
For men with advanced prostate cancer that no longer responds to standard hormone therapies, treatment options are limited – and time matters. As the disease progresses, the window for effective, less intensive treatments begins to close.
15
May 2026
Drug-resistant epilepsy affects millions of people worldwide and remains one of the most difficult neurological disorders to treat. For patients whose seizures continue despite medication, surgical removal of seizure-causing tissue can be effective.
15
May 2026
A comparative study, presented at ESGE Days 2026, has found that endoscopic sleeve gastroplasty (ESG) is associated with significantly greater short-term weight loss than oral semaglutide in adults with obesity.
15
May 2026
Researchers at The University of Texas Medical Branch (UTMB) have identified how a key enzyme called ATR protects DNA from breaking when cells copy damaged genetic material, a discovery that could affect how certain cancer drugs are developed.